Search research articles
Contact Us
Filters
Showing results (41-50 of 96) with videos related to
Page
of 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2021
Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study
Maud Toulmonde, Mehdi Brahmi, Antoine Giraud, et al.
Bulletin Du Cancer
|
September 15, 2022
[Practical management of PARP inhibitors: A French DELPHI consensus]
Frédéric Selle, Jean-Jacques Boffa, Gabriel Etienne, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 4, 2016
Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial
Roman Rouzier, Sébastien Gouy, Frédéric Selle, et al.
Gynecologic Oncology
|
November 19, 2022
Avelumab in patients with gestational trophoblastic tumors with resistance to polychemotherapy: Cohort B of the TROPHIMMUN phase 2 trial
Benoit You, Pierre-Adrien Bolze, Jean-Pierre Lotz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 5, 2019
The Nanocind Signature Is an Independent Prognosticator of Recurrence and Death in Uterine Leiomyosarcomas
Sabrina Croce, Tom Lesluyes, Carine Valle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 25, 2013
Functional decline in older patients with cancer receiving first-line chemotherapy
Stéphanie Hoppe, Muriel Rainfray, Marianne Fonck, et al.
Gynecologic Oncology
|
December 2, 2014
Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial
Anne Floquet, Ignace Vergote, Nicoletta Colombo, et al.
The Lancet. Oncology
|
March 22, 2015
Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial
Patricia Pautier, Anne Floquet, Christine Chevreau, et al.
Gynecologic Oncology
|
April 27, 2023
PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients
Thibault Gauduchon, Maria Kfoury, Domenica Lorusso, et al.
Gynecologic Oncology
|
July 30, 2020
Dose-intensive regimen treatment for small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT)
Félix Blanc-Durand, Claudia Lefeuvre-Plesse, Isabelle Ray-Coquard, et al.
Page
of 10
Search research articles
Search
Showing results (41-50 of 96) with videos related to
Sort By:
Page
of 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2021
Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study
Maud Toulmonde, Mehdi Brahmi, Antoine Giraud, et al.
Bulletin Du Cancer
|
September 15, 2022
[Practical management of PARP inhibitors: A French DELPHI consensus]
Frédéric Selle, Jean-Jacques Boffa, Gabriel Etienne, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 4, 2016
Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial
Roman Rouzier, Sébastien Gouy, Frédéric Selle, et al.
Gynecologic Oncology
|
November 19, 2022
Avelumab in patients with gestational trophoblastic tumors with resistance to polychemotherapy: Cohort B of the TROPHIMMUN phase 2 trial
Benoit You, Pierre-Adrien Bolze, Jean-Pierre Lotz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 5, 2019
The Nanocind Signature Is an Independent Prognosticator of Recurrence and Death in Uterine Leiomyosarcomas
Sabrina Croce, Tom Lesluyes, Carine Valle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 25, 2013
Functional decline in older patients with cancer receiving first-line chemotherapy
Stéphanie Hoppe, Muriel Rainfray, Marianne Fonck, et al.
Gynecologic Oncology
|
December 2, 2014
Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial
Anne Floquet, Ignace Vergote, Nicoletta Colombo, et al.
The Lancet. Oncology
|
March 22, 2015
Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial
Patricia Pautier, Anne Floquet, Christine Chevreau, et al.
Gynecologic Oncology
|
April 27, 2023
PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients
Thibault Gauduchon, Maria Kfoury, Domenica Lorusso, et al.
Gynecologic Oncology
|
July 30, 2020
Dose-intensive regimen treatment for small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT)
Félix Blanc-Durand, Claudia Lefeuvre-Plesse, Isabelle Ray-Coquard, et al.
Page
of 10